A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Appointments and advancements for Feb. 5, 2026
Appointments and advancements for Feb. 5, 2026
Financings for Feb. 5, 2026
Financings for Feb. 5, 2026
In the clinic for Feb. 5, 2026
In the clinic for Feb. 5, 2026
Other news to note for Feb. 5, 2026
Other news to note for Feb. 5, 2026
Regulatory actions for Feb. 5, 2026
Regulatory actions for Feb. 5, 2026
ALTx formed to drug pathway by which cancer cells become immortal
ALTx formed to drug pathway by which cancer cells become immortal
Yichang Humanwell Pharma divulges new benzodiazepine compounds
Yichang Humanwell Pharma divulges new benzodiazepine compounds
The United Bio-Technology discloses new GLP-1R agonists
The United Bio-Technology discloses new GLP-1R agonists
Chengdu companies patent new PET/SPECT imaging agents
Chengdu companies patent new PET/SPECT imaging agents
Yichang Humanwell Pharma reports new KCNQ2/3 activators
Yichang Humanwell Pharma reports new KCNQ2/3 activators
Other news to note for Feb. 5, 2026
Other news to note for Feb. 5, 2026
Financings for Feb. 4, 2026
Financings for Feb. 4, 2026
In the clinic for Feb. 4, 2026
In the clinic for Feb. 4, 2026
Other news to note for Feb. 4, 2026
Other news to note for Feb. 4, 2026
Regulatory actions for Feb. 4, 2026
Regulatory actions for Feb. 4, 2026
BARDA offers $100M in prize money for antiviral development
BARDA offers $100M in prize money for antiviral development
First-in-class fusion protein reverses T-cell exhaustion across multiple models
First-in-class fusion protein reverses T-cell exhaustion across multiple models
STK-026: a next-generation IL-12 therapy with improved safety profile
STK-026: a next-generation IL-12 therapy with improved safety profile
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page